High Flow Nasal Therapy (Physician) - Emphysema COPD Research Center

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD patients in the home (HiFloCOPD)

This is a parallel-group, prospective, randomized, controlled phase III trial to determine if high flow nasal therapy delivered via myAirvo 3 in addition to the usual COPD medical care increases the time to first moderate-severe exacerbation or all-cause mortality in patients with moderate to very severe COPD with recent exacerbation requiring hospitalization.

The myAirvo 3 is a humidifier with integrated flow generator designed to deliver air or oxygen via the Optiflow™ + Duet nasal cannula.

Primary Outcome:

Key inclusion criteria are:

GOLD stage III-IV COPD
Hospitalization with COPD exacerbation in the last 6 weeks
Standard treatment of COPD with either LAMA, ICS/LABA, LAMA/LABA
Current or past smokers of at least 10 pack years
Absence of OSA or being on NIV

ClinicalTrials.gov Identifier: NCT05204888

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD patients in the home (HiFloCOPD)

Primary Outcome:

Key inclusion criteria are:

ClinicalTrials.gov Identifier: NCT05204888

Thank You

For Contacting Us!